Commission Decision of 15 February 2006 concerning a specific financial contribution by the Community relating to the survey on TSE resistant PrP genes in goats presented by Cyprus for the year 2006 (notified under document number C(2006) 408) (Only the Greek text is authentic) (2006/140/EC)
EU Decision 2006/140 · Adopted 15 February 2006 · Extends to United Kingdom
Commission Decision
of 15 February 2006
concerning a specific financial contribution by the Community relating to the survey on TSE resistant PrP genes in goats presented by Cyprus for the year 2006
(notified under document number C(2006) 408)
(Only the Greek text is authentic)
(2006/140/EC)
THE COMMISSION OF THE EUROPEAN COMMUNITIES,
Having regard to the Treaty establishing the European Community,
Having regard to Council Decision 90/424/EEC of 26 June 1990 on expenditure in the veterinary fieldf1, and in particular Article 20 thereof,
Whereas:
(1)
Eradication of transmissible spongiform encephalopathies (TSEs) in small ruminants, including bovine spongiform encephalopathy (BSE) which is considered to be the cause of the fatal variant Creutzfeld Jacob disease in humans, is of major importance for animal health and consumer’s protection.
(2)
In sheep, selection towards resistant prion protein (PrP) genes is a major tool to achieve TSE eradication. Therefore minimum requirements for the establishment of breeding programmes for resistance to TSEs in sheep have been laid down in Commission Decision 2003/100/ECf2. Very limited information is however available on TSE resistant PrP genes in goats.
(3)
Verification of the existence of TSE resistant genotypes in goats is necessary in order to develop community legislation in the veterinary field, in particular on the control and possible eradication of TSEs in such animals.
(4)
A bi-annual survey on TSEs resistant genotypes in goats was submitted by the Cypriot authorities in 2005, with a view to obtain financial support from the Community. The objectives of the survey are to further investigate the PrP gene of the Cyprus goats in order to confirm the results of previous preliminary studies where specific PrP polymorphisms were found indicating resistance against TSEs and to evaluate the data in order to be able to determine the baseline prevalence of TSE resistant PrP genes in goats. Cyprus has a very high prevalence of TSEs in goats and is therefore the appropriate Member State to carry out such pilot project. The survey intends to start on 1 January 2006.
(5)
The survey will be executed by the Veterinary Services of the Ministry of Agriculture, Natural Resources and Environment of Cyprus. The Community Reference Laboratory for TSE will provide scientific supervision of the survey.
(6)
Pursuant to Article 3, paragraph 2, of Council Regulation (EC) No 1258/1999f3, veterinary and plant health measures undertaken in accordance with Community rules shall be financed under the Guarantee Section of the European Agricultural Guidance and Guarantee Fund; for financial control purposes, Articles 8 and 9 of Regulation (EC) No 1258/1999 apply.
(7)
A financial contribution from the Community shall be granted in so far as the actions provided for are effectively carried out and provided that the authorities furnish all the necessary information within the time limits provided for. For budgetary reasons, Community assistance is decided each year.
(8)
There is a need to clarify the rate to be used for the conversion of the payment applications submitted in national currency as defined in Article 1(d) of Council Regulation (EC) No 2799/98 of 15 December 1998 establishing agrimonetary arrangements for the eurof4.
(9)
The measures provided for in this Decision are in accordance with the opinion of the Standing Committee on the Food Chain and Animal Health,
HAS ADOPTED THIS DECISION:
Annotations to the whole text
Footnotes
- f1
-
OJ L 224, 18.8.1990, p. 19. Decision as last amended by Directive 2003/99/EC of the European Parliament and of the Council (OJ L 325, 12.12.2003, p. 31).
- f2
- f3
- f4
Contents
- 1Article 1
- 2Article 2
- 3Article 3
- 4Article 4
- 5Article 5
- Annex
- 1Financial assistance of the Community
- Chapter 2: Technical and financial reporting
- A:Technical report
- B:Statement on costs incurred for control
- 3Financial assistance of the Community
- Chapter 4: Technical and financial reporting
- A:Technical report
- B:Statement on costs incurred for control
1F1
The survey programme for TSE resistant PrP genes in goats presented by Cyprus is hereby approved for a period of 24 months starting from 1 January 2006 .
The financial assistance from the Community for the programme referred to in paragraph 1 covers the costs (VAT excluded) incurred by Cyprus for laboratory testing up to 100 % in accordance with Chapter 1 of the Annex for the year 2006 and Chapter 3 for the year 2007. The total assistance shall be a maximum amount of EUR 47 500 for the year 2006 and EUR 103 000 for the year 2007.
2
The financial assistance referred to under Article 1(2) shall be paid to Cyprus provided that the implementation of the programme shall be in conformity with the relevant provisions of Community law, including rules on competition and on the award of public contracts and subject to the conditions provided for in points (a) to (e):
bringing into force by 1 January 2006 the laws, regulations and administrative provisions for implementing the survey;
forwarding an intermediate yearly financial and technical evaluation covering the first eight months of each year of the survey, at the latest two months after the end of that period; the report shall conform to the model as set out in Chapter 2 of the Annex for the year 2006 and Chapter 4 thereof for the year 2007, accompanied by justifying evidence as to the costs incurred;
forwarding a final yearly report for each year of the survey by 31 March 2007 at the latest for the year 2006 and 31 March 2008 at the latest for the year 2007, on the overall execution and results of the survey for the whole period during which Community financial assistance was granted; the report shall contain a technical and financial evaluation covering the years 2006 and 2007, in accordance with the model as set out in Chapter 2 of the Annex for the year 2006 and Chapter 4 thereof for the year 2007, accompanied by justifying evidence as to the costs incurred;
these reports providing substantive and valuable technical and scientific information corresponding to the purpose of the Community intervention;
implementing the programme effectively.
When the time limit provided for in paragraph 1c) are not respected, the financial contribution shall be reduced by 25 % on 1 May, 50 % on 1 June, 75 % on 1 July and 100 % on 1 September of the calendar year following the survey year concerned.
3F1
The expenditure presented by Cyprus for a financial contribution by the Community shall be expressed in euro and shall exclude value added tax and other taxes.
The conversion rate for expenditure shall be the rate most recently set by the European Central Bank prior to the first day of the month in which the application is submitted by Cyprus.
4
This Decision shall apply from 1 January 2006.
5
This decision is addressed to the Republic of Cyprus.
1Financial assistance of the Community
| Costs | Number of units | Unitary cost in EUR | Total cost in EUR | Community assistence | |
|---|---|---|---|---|---|
| Sample collection | 70 hours | 21 | 1 470 | None | |
| Histological examination | 1 500 analyses | 3,5 | 5 250 | None | |
| PrP genotyping DNA sequencing | 750 analyses | 60 | 45 000 | Costs of maximum 750 analyses at maximum EUR 60 per analysis | |
| Rapid testing | Test kits and consumables | 250 tests | 14 | 3 500 | Costs of maximum 250 tests at maximum EUR 10 per test |
| Work | 60 hours | 20 | 1 200 | None | |
| Coordination and evaluation of data | 1 778 hours | 14,5 | 25 780 | None | |
| Traveling and accomodation costs CRL expert | 1 trip | 1 300 | 1 300 | None | |
| Total | Maximum EUR 47 500 | ||||
A:Technical report
-
Reporting period from … to …
Determination of PrP genotype by DNA sequencing
| Number of samples with at codon 146 amino acid: | ||||
|---|---|---|---|---|
| Aspartic acid | Serine | … | Other | |
| Histologically TSE + suspects, rapid test + | ||||
| Histologically TSE + suspects, rapid test – | ||||
| Histologically TSE – suspects, rapid test + | ||||
| Histologically TSE – suspects, rapid test – | ||||
| Healthy controls | ||||
B:Statement on costs incurred for control
-
Reporting period from … to …
-
Reference number of Commission Decision providing financial assistance: …
| Costs incurred related to | Number of units | Costs incurred during the reporting period (national currency) |
|---|---|---|
| PrP genotyping by DNA sequencing. Number of tests: | ||
| Rapid testing. Number of tests: | ||
| Rapid testing. Hours of work: |
3Financial assistance of the CommunityF1
| Costs | Number of units | Unitary cost in Euro | Total cost in Euro | Community assistance |
|---|---|---|---|---|
| PrP genotyping SNP analysis/DNA sequencing | 11 000 analyses | EUR 8 | EUR 88 000 | X1Costs of maximum 11 000 analyses at maximum EUR 8 per analysis |
| Rapid testing: test kits and consumables | 1 500 tests | EUR 10 | EUR 15 000 | Costs of maximum 1 500 tests at maximum EUR 10 per test |
| Total: | Maximum EUR 103 000 | |||
A:Technical reportF1
Reporting period from … to …
Determination of PrP genotype by SNP analysis/DNA sequencing
| Number of samples with amino acids at codon 146: | ||||
|---|---|---|---|---|
| Aspartic acid | Serine | … | Other | |
| Breed survey: Damascus | ||||
| Breed survey: Saanen | ||||
| Breed survey: Macheras Local | ||||
| Breed survey: Local | ||||
| Breed survey: French Alpine | ||||
| Scrapie-free herds (nuclei units) | ||||
| Histologically TSE + suspects, rapid test + | ||||
B:Statement on costs incurred for controlF1
Reporting period from … to …
Reference number of Commission Decision providing financial assistance: …
| Costs incurred related to | Number of units | Costs incurred during the reporting period (national currency) |
|---|---|---|
| PrP genotyping by SNP analysis/DNA sequencing. Number of tests: | ||
| Rapid testing. Number of tests |